Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia

Q. Li, H. Li, K. Roughton, X. Wang, G. Kroemer, K. Blomgren, C. Zhu

    Research output: Contribution to journalArticlepeer-review

    126 Citations (Scopus)

    Abstract

    Lithium is used in the treatment of bipolar mood disorder. Reportedly, lithium can be neuroprotective in models of adult brain ischemia. The purpose of this study was to evaluate the effects of lithium in a model of neonatal hypoxic-ischemic brain injury. Nine-day-old male rats were subjected to unilateral hypoxia-ischemia (HI) and 2 mmol/kg lithium chloride was injected i.p. immediately after the insult. Additional lithium injections, 1 mmol/kg, were administered at 24-h intervals. Pups were killed 6, 24 or 72 h after HI. Lithium reduced the infarct volume from 24.7±2.9 to 13.8±3.3 mm3 (44.1%) and total tissue loss (degeneration + lack of growth) from 67.4±4.4 to 38.4±5.9 mm3 (43.1%) compared with vehicle at 72 h after HI. Injury was reduced in the cortex, hippocampus, thalamus and striatum. Lithium reduced the ischemia-induced dephosphorylation of glycogen synthase kinase-3β and extracellular signal-regulated kinase, the activation of calpain and caspase-3, the mitochondrial release of cytochrome c and apoptosis-inducing factor, as well as autophagy. We conclude that lithium could mitigate the brain injury after HI by inhibiting neuronal apoptosis. The lithium doses used were in the same range as those used in bipolar patients, suggesting that lithium might be safely used for the avoidance of neonatal brain injury.

    Original languageEnglish
    Article numbere56
    JournalCell Death and Disease
    Volume1
    Issue number7
    DOIs
    Publication statusPublished - 1 Jul 2010

    Keywords

    • Apoptosis-inducing factor (AIF)
    • Asphyxia
    • Caspase
    • ERK
    • GSK-3

    Cite this